Subodh Verma




Please note: Dr. Verma will not take students in summer.

Dr. Subodh Verma is an internationally renowned cardiac surgeon-scientist and Professor at the University of Toronto. He is the current Canada Research Chair in Cardiovascular Surgery, having previously served as the Canada Research Chair in Atherosclerosis (2007-2017). Dr. Verma was recently awarded the 2021 Lister Prize in Surgery from the University of Toronto in recognition of his outstanding and continuing productivity of international stature. He is a past recipient of the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. He is an appointee of the American Association of Thoracic Surgeons (AATS) and a member of the College of New Scholars, Artists and Scientists, Royal Society of Canada. According to Google Scholar in April 2021, Dr. Verma has an h-index of 100 and his work has been cited over 50,000 times.

Dr. Verma has published extensively in highly impactful journals like the NEJM, Lancet, Circulation, JACC, Nature, and JCI. He is an Associate Editor of the European Heart Journal. Dr. Verma is an active contributor to Canadian clinical practice guidelines and co-authored the recently updated recommendations for atrial fibrillation, antiplatelet therapy, diabetes, and heart failure; he was a member of the 2018 AATS consensus guidelines committee on bicuspid aortic valve-related aortopathy. Dr. Verma has served in various capacities on the American Heart Association Council on Cardiovascular Surgery and Anesthesia since 2008.

Dr. Verma had/has leadership roles on 10 contemporary global heart failure trials – several of which have let to paradigm changes in how individuals all around the world who live with diabetes and heart failure are now managed. He founded and oversees the CardioLink platform at St Michael’s Hospital that is conducting cardiometabolic and surgically oriented RCTs and translational studies.

Dr. Verma leads a dynamic pre-clinical and translational research team that leverages pre-clinical disease models and clinical trial-derived data to identify novel mediators of cardiovascular and cardiometabolic disease as well as answer timely and relevant healthcare questions. His research has yielded 2 United States patents and is supported by several national peer-reviewed grants.


Recent Publications

  1. Shah, SJ, Sharma, K, Borlaug, BA, Butler, J, Davies, M, Kitzman, DW et al.. Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM trials. Eur Heart J. 2024; :. doi: 10.1093/eurheartj/ehae322. PubMed PMID:38739118 .
  2. Solomon, SD, Ostrominski, JW, Vaduganathan, M, Claggett, B, Jhund, PS, Desai, AS et al.. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial. Eur J Heart Fail. 2024; :. doi: 10.1002/ejhf.3266. PubMed PMID:38733212 .
  3. Butler, J, Shah, SJ, Petrie, MC, Borlaug, BA, Abildstrøm, SZ, Davies, MJ et al.. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024;403 (10437):1635-1648. doi: 10.1016/S0140-6736(24)00469-0. PubMed PMID:38599221 .
  4. Kosiborod, MN, Petrie, MC, Borlaug, BA, Butler, J, Davies, MJ, Hovingh, GK et al.. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med. 2024;390 (15):1394-1407. doi: 10.1056/NEJMoa2313917. PubMed PMID:38587233 .
  5. Pandey, A, Patel, KV, Segar, MW, Ayers, C, Linge, J, Leinhard, OD et al.. Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial. J Cachexia Sarcopenia Muscle. 2024; :. doi: 10.1002/jcsm.13445. PubMed PMID:38561962 .
  6. Sattar, N, Butler, J, Lee, MMY, Harrington, J, Sharma, A, Zannad, F et al.. Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: Principal findings and meta-analysis with the DELIVER trial. Eur J Heart Fail. 2024; :. doi: 10.1002/ejhf.3221. PubMed PMID:38558521 .
  7. Bakbak, E, Krishnaraj, A, Bhatt, DL, Quan, A, Park, B, Bakbak, AI et al.. Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial. Med. 2024; :. doi: 10.1016/j.medj.2024.03.009. PubMed PMID:38552629 .
  8. Harrington, J, Felker, GM, Januzzi, JL, Lam, CSP, Lingvay, I, Pagidipati, NJ et al.. Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions. Curr Cardiol Rep. 2024;26 (3):61-71. doi: 10.1007/s11886-023-02016-z. PubMed PMID:38551786 .
  9. Zimerman, A, Wiviott, SD, Park, JG, Murphy, SA, Ran, X, Bramson, CR et al.. Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial. Eur J Prev Cardiol. 2024; :. doi: 10.1093/eurjpc/zwae090. PubMed PMID:38484368 .
  10. Park, B, Bakbak, E, Teoh, H, Krishnaraj, A, Dennis, F, Quan, A et al.. GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage. Am J Physiol Heart Circ Physiol. 2024;326 (5):H1159-H1176. doi: 10.1152/ajpheart.00574.2023. PubMed PMID:38426865 .
Search PubMed

Affiliations & Other Activities

  • Cardiac Surgeon, Division of Cardiology , St. Michael’s Hospital
  • Professor of Surgery and Pharmacology & Toxicology, University of Toronto
  • Canada Research Chair in Cardiovascular Surgery